Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i think we all do...
it's new to me, thanks for posting :)
Jim Profit
there is no bottom!
UPDV was a scam from day one IMHO
awesome :D
everybody with a brain will now run from this POS like forrest...
@Ericus
great job tnx, hope these fraudsters don't get away with the millions they stole from the believers! but i guess they will
Jim Profit
there is none, except that there are allot of German bagholders that believed the PR story...
if it were a secret... he wouldn't know it!
Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Tuesday June 3, 11:51 am ET
- Study Published in Journal Molecular Vision -
- Results Show Good Distribution of Bevasiranib to Retina and RPE Cells after a Single Intravitreal Injection -
MIAMI, June 3 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK - News) today announced that a study published in the peer-reviewed journal Molecular Vision demonstrates that bevasiranib, its siRNA (small interfering RNA) agent is distributed throughout the eye, including extensive uptake into the retina. In two tissue distribution and pharmacokinetic studies in rabbits, results showed that bevasiranib was present in the retina and in targeted retinal pigment epithelium (RPE) cells following intravitreal injection. Bevasiranib is a gene-silencing agent designed to shut down the production of vascular endothelial growth factor (VEGF), a primary cause of the new blood vessel growth, or neovascularization, associated with vision loss in patients with wet age-related macular degeneration, or wet AMD. The efficacy and safety of bevasiranib are currently being assessed in the COBALT study, an international Phase III trial for the treatment of wet AMD.
"Importantly, these data indicate that following intravitreal injection, bevasiranib distributes to the ocular structures relevant to the VEGF-induced neovascularization associated with vision loss in wet AMD, and we believe this animal data provides support for the use of bevasiranib in our ongoing pivotal Phase III trial for the treatment of wet AMD," said Samuel Reich, Executive Vice President of OPKO Ophthalmics. "It is noteworthy that bevasiranib was distributed to the RPE cells, since we believe that even a fraction of the tissue-associated bevasiranib entering the RPE cell is likely to be effective in specifically suppressing VEGF production."
The Molecular Vision study can be accessed at
http://www.molvis.org/molvis/v14/a119/
"Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes," NS Dejneka, S Wan, OS Bond, DJ Kornbrust, SJ Reich, Molecular Vision, Volume 14, May 28, 2008
Source: OPKO Health, Inc.
Jim Profit
you can apply as mod above the ibox... just need to post some posts
your job would be to keep the board clean...
looks like a third leg could happen before the normal 9 month walkdown as lowtrade allways said :)
hmm i forgot that it would trade where it is now again soon if they split 1:1000 ROFL ;)
they should reverse it 1000:1 than there is no danger to get delisted from the german exchanges... that's where they normally dump their worthless shares!
Jim Profit
because those CEO's are greedy... easy money!
yes i am, but most germans don't know how to read filings... i do!
most of them believe the lies they were told by the company and promoters...
:)
germans... ;)
1.12 x 1.20 :D
1.10 x 1.15
that would be nice :)
at least not playable with IB :(
the volume would be probably higher if "somebody knew something", but maybe someone does and isn't selling?
fingers crossed...
i like to have the dollar back :)
101/105
so you moved to the next scam? UMNG? LOL
the s#*! is about to hit the fan soon IMHO
thank you! :)
take your time... i hope to be able to grab some more tomorrow cheap ;)
hehe, that already was my impression ;)
i liked what i heard and understood...
was a bit difficult for me as a german to understand all that was said :)
don't think the real numbers are released by now...
yep, i love cornell! when i see cornell i know i have to run! :D
life can be so easy! ;)
R/S next?
he meant that his feelings worked very well for him in the past ;)
actually there is no moderator on this board, i resigned as mod...
i'm currently to busy with the real world ;)
if anyone wants to be mod, just make some posts and apply as mod above the ibox!
thanks
they cooked the books LMAO
Nano-Proprietary, Inc. Grant Application Selected for Award by the Department of Energy
Monday May 12, 9:10 am ET
AUSTIN, TX--(MARKET WIRE)--May 12, 2008 -- Austin, Texas-based Nano-Proprietary, Inc. (OTC BB:NNPP.OB - News) announced that its subsidiary Applied Nanotech, Inc. ("ANI") has been selected to be awarded a new phase I Small Business Innovation Research Program grant by the U.S. Department of Energy in the approximate amount of $100,000.
The purpose of the grant is to develop nanoparticle inks and processes for printing photovoltaic cells for use in solar cell applications. The goal is to lower the cost of fabrication, while maintaining or improving cell performance over conventional technologies.
"We are pleased to be selected for this award," said Dr. Zvi Yaniv, President and Chief Executive Officer of ANI. "This grant allows us to expand our field of application to green energy, while capitalizing on our achievements in the development work related to metallic nanoparticles ink."
More information is available at the Department of Energy Website at http://www.science.doe.gov/sbir/awards_abstracts/sbirsttr/cycle26/phase1/p1_award.htm.
Source: Nano-Proprietary, Inc.
i wouldn't call it perfect but yes... fraud fits :)
OPKO Health Acquires Company Developing Novel Glaucoma Therapy
Wednesday May 7, 7:45 am ET
-Vidus Ocular's Innovative Aquashunt(TM) Device Offers Potential Advantages-
-Glaucoma Affects 2.4 Million Americans and 60 Million People Worldwide-
MIAMI, May 7 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK - News) today announced that it has acquired Vidus Ocular, Inc., a privately held company that is developing Aquashunt(TM), an innovative shunt to treat glaucoma, the second leading cause of blindness in the U.S., in an all-stock transaction. Aquashunt is an implantable physiologic device that is designed to address the shortcomings of current glaucoma treatments. Glaucoma is presently treated with drugs, lasers and surgery, but each has limitations, including efficacy, safety and cost issues.
The patented Aquashunt device was designed by Dr. Bruce Shields, Chairman Emeritus of the Department of Ophthalmology and Visual Sciences at the Yale University School of Medicine. Aquashunt is a simple but elegant approach that uses biocompatible materials and is designed for rapid, simple, minimally traumatic insertion. Aquashunt is intended to reduce intraocular pressure physiologically by allowing excess fluid in the eye to exit naturally. It currently is in preclinical testing and human studies are expected to begin during the fourth quarter of this year.
"Aquashunt is designed to offer a new therapeutic option with significant benefits compared to current therapies," said Dr. Naveed Shams, Chief Medical Officer and Senior Vice President of Research and Development of OPKO. "As a device, it also has the potential for a relatively rapid and straightforward development and regulatory pathway. We believe the acquisition of Vidus Ocular is an excellent strategic fit with our ophthalmics business, providing us with the potential to market an innovative product that addresses a serious disease affecting millions of people."
Glaucoma occurs when fluid accumulating in the eye raises the intraocular pressure and causes the optic nerve to degenerate, potentially leading to irreversible vision loss. Glaucoma is increasing in prevalence as the population ages, currently affecting an estimated 2.4 million people in the U.S. and about 60 million people worldwide.
"We designed Aquashunt with the goal of translating our extensive experience in treating glaucoma into a new type of therapy that would leverage physiologic principles to treat patients more safely, effectively and economically," said Dr. Shields, Chief Scientific and Medical Officer of Vidus Ocular. "Preclinical data on the device are encouraging, and we believe that OPKO is an ideal partner to assume responsibility for the development and commercialization of this potentially important product."
Glaucoma is a significant worldwide health problem affecting patients globally. According to the terms of the agreement, OPKO will also work with Yale University on a number of initiatives to increase access to the Vidus shunt technology in the developing world.
Source: OPKO Health, Inc.